TickerFacts.

CRISPR Therapeutics AG (CRSP): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$345.01M
Year ended 2025-12-31
-$369.58M
Trailing 12 months to 2026-06-30
$538.97M2016-12-31: -$52.86M2017-12-31: -$70.09M2018-12-31: -$96.24M2019-12-31: $56.68M2020-12-31: -$238.37M2021-12-31: $538.97M2022-12-31: -$495.74M2023-12-31: -$260.38M2024-12-31: -$142.77M2025-12-31: -$345.01M-$345.01M
2016-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$345.01Mn/m2026-02-12, From 2025-01-01
2024-12-31-$142.77Mn/m2026-02-12, From 2024-01-01
2023-12-31-$260.38Mn/m2026-02-12, From 2023-01-01
2022-12-31-$495.74Mn/m2025-02-11, From 2022-01-01
2021-12-31$538.97Mn/m2024-02-21, From 2021-01-01
2020-12-31-$238.37Mn/m2023-02-21, From 2020-01-01
2019-12-31$56.68Mn/m2022-02-15, From 2019-01-01
2018-12-31-$96.24Mn/m2021-02-16, From 2018-01-01
2017-12-31-$70.09Mn/m2020-02-12, From 2017-01-01
2016-12-31-$52.86Mn/a2019-02-25, From 2016-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
CRISPR Therapeutics AG (CRSP)2025-12-31-$345.01Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$30.24Mn/m
Dyadic International Inc (DYAI)2025-12-31-$5.70Mn/m
CG Oncology, Inc. (CGON)2025-12-31-$132.35Mn/m
Ocugen, Inc. (OCGN)2025-12-31-$56.96Mn/m
Prime Medicine, Inc. (PRME)2025-12-31-$162.56Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$718.0Kn/m
Aligos Therapeutics, Inc. (ALGS)2025-12-31-$82.50Mn/m
DBV Technologies S.A. (DBVT)2025-12-31-$121.18Mn/m

Compare CRSP, SRZN, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗